Trial · NCT06965244
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
NCT06965244, Phase 3, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus. Trials, record NCT06965244. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06965244
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
- NCT number
- NCT06965244
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 122 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Lenalidomide, Methotrexate (MTX)
- First posted
- 2025-05-11
- Last updated
- 2025-05-11
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who achieve decrease of at least 50% from baseline in the CLASI activity (CLASI-A) score | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Percentage of patients reaching CLASI-A 70 | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Proportion of participants who achieve complete or almost complete response (CLASI-A 0-3) | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Percentage of patients reaching CLASI-A 70 | At week 24 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Proportion of participants who achieve complete or almost complete response (CLASI-A 0-3) | At week 24 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Variation of Quality of life using DLQI | At week 16 | DLQI : Dermatology Life Quality Index |
| Secondary | Variation of Quality of life using DLQI | At week 24 | DLQI : Dermatology Life Quality Index |
| Secondary | SLE activity using SLEDAI | Up to 24 weeks | SLEDAI : Systemic Lupus Erythematosus Disease Activity Index |
| Secondary | SLE flare using SENELA-SLEDAI Flare Index (SFI) | Up to 24 weeks | SELENA : Safety of Estrogens in Lupus Erythematosus National Assessment SLEDAI : Systemic Lupus Erythematosus Disease Activity Index |
| Secondary | Variation of GCs dose | Between inclusion and week 24. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06965244
GET https://conductscience.org/api/trials/v1/NCT06965244/registered